News en Coronavirus information <span>Coronavirus information </span> <span><span>S.Anand</span></span> <span>Thu, 27/02/2020 - 12:11</span> <div class="field field--name-field-date field--type-datetime field--label-hidden field--item"><time datetime="2020-02-27T12:00:00Z">27 February 2020</time></div> <div class="field field--name-body field--type-text-with-summary field--label-hidden field--item"><p><span><span>Extensive information about coronavirus (COVID-19) is available on the <a href="">NHS website</a>. If you are worried that you may have coronavirus, please call NHS 111 for advice on what to do next.  </span></span></p> <p><span><span><span>Please note: Harefield and Royal Brompton hospitals are not testing centres for coronavirus. NHS 111 will be able to direct you appropriately. </span></span></span></p></div> Thu, 27 Feb 2020 12:11:57 +0000 S.Anand 2649 at New baby mannequin improves training for clinicians <span>New baby mannequin improves training for clinicians</span> <span><span>S.Anand</span></span> <span>Thu, 20/02/2020 - 12:19</span> <div class="field field--name-field-date field--type-datetime field--label-hidden field--item"><time datetime="2020-02-20T12:00:00Z">20 February 2020</time></div> <div class="field field--name-body field--type-text-with-summary field--label-hidden field--item"><p><span><span><span>A new state-of-the-art mannequin has been introduced to Royal Brompton Hospital to help staff prepare for complex clinical scenarios. </span></span></span></p> <p><span><span><span>The lifelike mannequin, called Harley Baby II, will allow clinicians to simulate emergency cardiac (heart) procedures in infants in a more realistic way than ever before.</span></span></span></p> <p><img alt="Harley Baby mannequin" data-entity-type="file" data-entity-uuid="2fada9bb-e4ed-40dd-be99-1ae4fc89924c" src="" class="align-right" /><span><span><span>Harley Baby II is made of high-quality silicone with a replica of a toddler’s heart. It has reinforced skin and fat layers, with an incision down the chest. Harley Baby II also has a metal chest opening mechanism and three chest drains (tubes). </span></span></span></p> <p><span><span><span>Royal Brompton’s consultant paediatric and adult cardiac surgeon, Mr Andreas Hoschtitzky,<strong> </strong>said: “Harley Baby II is incredibly lifelike. It allows us to simulate cardiac surgery on an infant in a very realistic way, giving our clinicians confidence in real-life situations. It also enables us to analyse</span></span></span><span><span><span> any issues that arise during critical clinical scenario training and take the appropriate steps to change the way our teams work, and improve patient safety.”</span></span></span></p> <p><span><span><span>Open chest surgery in infants is a high impact, critical event. Through highly realistic simulations with Harley Baby II, patient care will be improved  through  enhanced performance and team work.</span></span></span></p> <p><span><span><span>The new mannequin was co-designed with clinicians, the Trust’s <a href="">SPRinT</a> team and <a href="">Lifecast</a>. </span></span></span></p> <p><span><span><span>The Trust’s congenital heart disease (CHD) centre for children is one of the largest in the UK. The teams care for congenital heart disease patients from pre-birth and through to adulthood and support young people to make the transition from paediatric to adult services. </span></span></span></p></div> Thu, 20 Feb 2020 12:19:42 +0000 S.Anand 2644 at Harefield transformative heart surgery featured in Channel 5 TV programme <span>Harefield transformative heart surgery featured in Channel 5 TV programme</span> <span><span>H.Virgo</span></span> <span>Fri, 07/02/2020 - 14:44</span> <div class="field field--name-field-date field--type-datetime field--label-hidden field--item"><time datetime="2020-02-07T12:00:00Z">7 February 2020</time></div> <div class="field field--name-body field--type-text-with-summary field--label-hidden field--item"><p><span><span><span><span>Harefield Hospital has featured in a popular Channel 5 TV programme that looks at how medical supplies are shipped across Europe: <strong><em>Inside DHL: The World’s biggest delivery company</em></strong>. The programme follows Harefield patient 30-year-old Enzo, who needs an aortic valve replacement, and the life-changing surgery he receives from a team led by Mr Toufan Bahrami, consultant cardiac surgeon. </span></span></span></span></p> <p><span><span><span><span>The programme follows Enzo as he undergoes minimally invasive valve surgery. His <span>valve is replaced through a small incision in the middle of his chest and with a bovine resilia valve made with tissue — from a cow. The team at </span>Harefield Hospital was one of the first in the world to implant this type of valve.<span> It <span>fits neatly into the aorta in the same place as the damaged valve so does not need to be stitched into place — allowing for a faster recovery time. </span></span>The new valve is designed to provide younger, active patients with an alternative option to mechanical valves that can last up to 30 years and does not require life-long anticoagulation with blood thinners. </span></span></span></span></p> <p><span><span><span><span>The replacement valves are sourced from over 350 miles away in the Netherlands. As the valves are made from animal tissue, they are extremely temperature sensitive and must be monitored rigorously throughout the journey. The Channel 5 programme follows the 18- hour journey from Eindhoven to Heathrow via Brussels and Calais, and then to Harefield Hospital where they arrive into the safe hands of Mr Bahrami.</span></span></span></span></p> <p><span><span><span><span>Commenting on the procedure, Mr Bahrami said: “As one of Europe’s leading specialist centres for the treatment of heart valve disease we offer some of the most pioneering innovation in minimally invasive surgery. This new valve is a game-changer and is ideal for young patients just like Enzo who need an aortic valve replacement.” </span></span></span></span></p> <p><span><span><span><span>Five months after his surgery, Enzo is fully recovered. Talking about his surgery he says: “My life has been changed. The surgeon is obviously the main person but you’ve also got to think about the person who has invented the product, the person who has delivered it. There are so many people involved for me just to get better. I can’t thank them enough. I’m so grateful.”</span></span></span></span></p> <p><span><span><span>Harefield Hospital has been at the forefront of minimally invasive cardiac surgery including aortic and mitral valve repair and replacement, and bypass surgery. More than 3000 procedures have been performed at the hospital through keyhole surgery since 2000. </span></span></span></p></div> Fri, 07 Feb 2020 14:44:20 +0000 H.Virgo 2633 at Guy’s and St Thomas’ and Royal Brompton & Harefield joint statement regarding plans for closer working <span>Guy’s and St Thomas’ and Royal Brompton & Harefield joint statement regarding plans for closer working</span> <span><span>S.Anand</span></span> <span>Thu, 30/01/2020 - 12:51</span> <div class="field field--name-field-date field--type-datetime field--label-hidden field--item"><time datetime="2020-01-30T12:00:00Z">30 January 2020</time></div> <div class="field field--name-body field--type-text-with-summary field--label-hidden field--item"><p><span><span><span><span><span><span>Since 2017, Guy’s and St Thomas’ and Royal Brompton & Harefield NHS Foundation Trusts have been working together, and with colleagues across King’s Health Partners, to develop plans to transform care for people with heart and lung disease. </span></span></span></span></span></span></p> <p><span><span><span><span><span><span>Our two Trusts have a long history of being at the forefront of patient care and research. Throughout our discussions, together, and with our wider partnership, we have remained focused on how we can use our collective clinical and academic expertise to provide the best possible care to patients, meet all national standards for paediatric congenital heart disease and ensure the long-term future of the specialist services currently provided at Royal Brompton Hospital.  </span></span></span></span></span></span></p> <p><span><span><span><span><span><span>It has become increasingly clear to the Boards of both Trusts that full integration of the services provided by Royal Brompton & Harefield with those at Guy’s and St Thomas’, in effect an agreed merger, is the best and most positive way of securing these aims and the collective vision of the wider partnership. This includes the creation of a hub for highly specialised clinical academic cardio-respiratory services at the St Thomas’ site.</span></span></span></span></span></span></p> <p><span><span><span><span><span><span>The Boards of both Trusts are confident that by formally bringing together our respective organisations and the shared expertise of our clinical and academic teams, we can significantly improve care and outcomes for people with cardiovascular and respiratory disease.  This ambitious venture, in partnership with King’s College Hospital NHS Foundation Trust and our academic partners, will create a centre of national excellence for the care of adults and children, which will sit at the heart of a population health system working together to significantly reduce the burden of these conditions.  </span></span></span></span></span></span></p> <p><span><span><span><span><span><span>At their public board meeting, NHS England have reiterated their support for our approach to closer working between our two Trusts. They have also confirmed their backing for a merger of the two organisations. Further details of this transaction, the process, and the next steps will be set out in a ‘letter of intent’ between the Trusts, which we expect to be agreed shortly.  </span></span></span></span></span></span></p> <p><span><span><span><span><span><span>We wholeheartedly welcome this news. The proposals set out by NHS England today also provide the necessary assurances to protect and maintain the provision of high quality services to the population of north west London and continued cardio-respiratory research excellence across London; and we will be taking this forward with our NHS partners and with King’s College London and Imperial College, London. </span></span></span></span></span></span></p> <p><span><span><span><span><span><span>Clinicians and patients have already been involved in developing these proposals, and we will continue to work closely with them as we take forward our plans, which will also be subject to any engagement, consultation and regulatory approval required.</span></span></span></span></span></span></p> <hr /><p>The papers for NHS England and NHS Improvement board meetings on 30 January 2020 are available to view <a href="">here</a>. </p></div> Thu, 30 Jan 2020 12:51:16 +0000 S.Anand 2598 at New heart implant reduces risk of stroke <span>New heart implant reduces risk of stroke </span> <span><span>H.Virgo</span></span> <span>Tue, 07/01/2020 - 10:13</span> <div class="field field--name-field-date field--type-datetime field--label-hidden field--item"><time datetime="2020-01-07T12:00:00Z">7 January 2020</time></div> <div class="field field--name-body field--type-text-with-summary field--label-hidden field--item"><p><span><span>A new heart implant called ‘Watchman FLX’ that can help reduce the risk of stroke by up to 80 per cent has recently been made available in the UK. </span></span></p> <p><span><span>The device sits inside the pouch in the left chamber of the heart where blood clots typically form and is an updated version of an older system with the same name. It is being offered to patients with atrial fibrillation, the most common form of irregular heartbeat affecting around one million people in the UK, and has been implanted at the Royal Brompton Hospital since August 2019. </span></span></p> <p><span><span>Patients with atrial fibrillation often rely on long-term blood-thinning drugs, but these can increase the risk of uncontrollable bleeding. The new Watchman device offers a permanent alternative to medication by sitting within the heart pouch and stops clots being able to escape and cause a stroke.</span></span></p> <p><span><span>The new device is available in five different widths and is made of a flexible, thin metal that moulds to fit every person's anatomy. </span></span></p> <p><span><span>Royal Brompton’s honorary co<span>nsultant cardiologist and electrophysiologist, </span>Dr Sandeep Panikker, who has fitted over 20 patients with the device, said: “All patients are different and so are their hearts. The previous version of the device couldn’t fit smaller, bigger and irregular shapes.’ </span></span></p> <p><span><span>Dr Panikker said the device is also a good option for people who forget to or are unable to take medication. “With blood thinners, you have to be committed to taking them for the rest of your life. Lots of people don't want to do this. If you miss a dose, there can be problems. But with this device you don’t have to worry.”</span></span></p> <p><span><span>You can find out more about the device and how it works <a href="">here</a>.</span></span></p></div> Tue, 07 Jan 2020 10:13:09 +0000 H.Virgo 2592 at Face mask can help combat mild cases of sleep condition <span>Face mask can help combat mild cases of sleep condition</span> <span><span>H.Virgo</span></span> <span>Tue, 03/12/2019 - 09:48</span> <div class="field field--name-field-date field--type-datetime field--label-hidden field--item"><time datetime="2019-12-03T12:00:00Z">3 December 2019</time></div> <div class="field field--name-body field--type-text-with-summary field--label-hidden field--item"><p><span><span><span>A night time face mask can improve energy levels and vitality in people who suffer from the condition sleep apnoea, which is associated with snoring and breathing problems at night.</span></span></span> <span><span><span><span><span><span><span>This is the finding from a new study of over 300 patients, published in the journal The Lancet Respiratory Medicine, led by Imperial College London.</span></span></span></span></span></span></span></p> <p><span><span><span><span><span><span><span>The research, conducted at 11 NHS sleep centres across the UK including the Royal Brompton & Harefield NHS Foundation Trust, is one of the first to investigate the use of the treatment for mild cases of sleep apnoea. The mask – called a CPAP machine - is currently only recommended for people whose sleep apnoea is moderate to severe.</span></span></span></span></span></span></span></p> <p><span><span><span><span><span><span><span>Sleep apnoea affects over one billion adults globally and causes the airways to become too narrow during sleep, causing people to briefly stop breathing many times throughout the night.  It can also trigger loud snoring, and cause frequent awakening from sleep, and subsequent daytime sleepiness.</span></span></span></span></span></span></span></p> <p><span><span><span><span><span><span><span>Severe cases of sleep apnoea are thought to affect up to 1.5 million in the UK, with some estimates suggesting up to eight million people in the UK may have a mild form of the condition.</span></span></span></span></span></span></span></p> <p><span><span><span><span><span><span><span>One treatment is a mask that fits over the nose or mouth called a continuous positive airway pressure (CPAP) machine, which gently pushes air into the mouth and throat, keeping the airways open.</span></span></span></span></span></span></span></p> <p><span><span><span><span><span><span><span>Although previous trials have found a CPAP machine to improve symptoms of moderate to severe cases of the condition, this is the first large trial to find that mild cases of sleep apnoea can also be treated with this technology.</span></span></span></span></span></span></span></p> <p><span><span><span><span><span><span><span>Mary Morrell, Professor of Sleep and Respiratory Physiology at the National Heart and Lung Institute at Imperial, and lead author of the research,</span></span></span> <span><span><span>said: “We are seeing increasing cases of sleep apnoea, and in a wide range of patients. Although the condition was previously thought to mainly affect overweight men, we now know it also strikes post-menopausal women, the elderly, and even children."</span></span></span></span></span></span></span></p> <p><span><span><span><span><span><span><span>Professor Morrell, who is also honorary researcher at the Royal Brompton Hospital, added:<strong> </strong>"Around 60 per cent of all cases of sleep apnoea are classed as mild, but until now we didn’t know whether a CPAP would be helpful to these patients.”</span></span></span></span></span></span></span></p> <p><span><span><span><span><span><span><span>In the study, 115 patients were asked to use the CPAP for three months, while 118 received standard care for mild sleep apnoea, which includes advice on improving sleep and avoiding anything that can exacerbate the condition, such as drinking alcohol before bed.</span></span></span></span></span></span></span></p> <p><span><span><span><span><span><span><span>The research revealed those who used the CPAP machine had an improvement of 10 points on a so-called vitality scale, compared to those who received standard care.The vitality scale assesses a range of factors such as sleep quality, energy levels and daytime sleepiness. The researchers also saw improvements in a number of additional factors among the patients who used the CPAP, including fatigue, depression, and social and emotional functioning.</span></span></span></span></span></span></span></p> <p><span><span><span><span><span><span><span>The researchers explain they have not yet conducted an economic analysis of the cost to the NHS of treating mild cases of sleep apnoea with a CPAP machine. In previous studies they have shown that, if used correctly, the machines are cost-effective (using the criteria for cost-effectiveness defined by the National Institute for Health and Care Excellence)  </span></span></span></span></span></span></span></p> <p><span><span><span><span><strong><span><span><span>Dr Julia Kelly, first author of the paper, said: “Currently the NHS doesn’t routinely offer CPAP machines to cases of mild sleep apnoea, but our research suggests this treatment should now be considered.”</span></span></span></strong></span></span></span></span></p> <p><span><span><span><span><span><span><span>The research was funded by ResMed, who manufacture CPAP machines, but the funder had no involvement in the trial methods or data analysis.</span></span></span></span></span></span></span></p></div> Tue, 03 Dec 2019 09:48:30 +0000 H.Virgo 2586 at Children's services praised by CQC <span>Children's services praised by CQC</span> <span><span>H.Virgo</span></span> <span>Tue, 19/11/2019 - 16:51</span> <div class="field field--name-field-date field--type-datetime field--label-hidden field--item"><time datetime="2019-11-19T12:00:00Z">19 November 2019</time></div> <div class="field field--name-body field--type-text-with-summary field--label-hidden field--item"><p><span><span><span><span>The latest Children and Young People’s Patient Experience Survey, published on 19<sup>th</sup> November by the Care Quality Commission, has identified Royal Brompton & Harefield NHS Foundation Trust as performing <strong>‘much better than expected’</strong> when compared to other Trusts, f</span>or the experiences of children aged up to seven years old. The Trust’s results were also “<strong>better than expected</strong>” in the eight to 15 year-old category. </span></span></span></p> <p><span><span><span>The national survey involved 33,179 children and young people, including their parents and carers, across 129 acute and specialist NHS trusts across England. Between February and June 2019, questionnaires were sent out to those who attended hospital in November and December 2018 as inpatients or day-case patients.</span></span></span></p> <p><span><span><span>Compared to other trusts, Royal Brompton and Harefield hospitals scored particularly well, with ratings that were better than the national average on 31 of the questions, and the rest being in line with the rest of the country.</span></span></span></p> <p><span><span><span>Key areas where the Trust’s scores were rated ‘better’ than most others included: </span></span></span></p> <ul><li><span><span><span><span>the overall experience of parents feeling their child was<span> well</span> looked after </span></span></span></span></li> <li><span><span><span><span><span>the availability of staff when a child needed someone to play with, or when privacy was needed</span></span></span></span></span></li> <li><span><span><span><span>the approach taken to keeping young people and their families informed and involved in their care</span></span></span></span></li> <li><span><span><span><span><span>the level of dignity and respect shown to young patients and their families.</span></span></span></span></span></li> </ul><p><span><span>Commenting on the survey results, Joy Godden, director of nursing and clinical governance, said: “</span></span><span><span>Involving and listening to children and their families is an important part of our work, and we regularly act on feedback telling us what we’re doing well and where we might improve. These encouraging results in the official CQC young people’s survey are a very welcome endorsement of our approach, and are a credit to everyone in the Trust who works in children’s services.”</span></span></p></div> Tue, 19 Nov 2019 16:51:33 +0000 H.Virgo 2569 at Royal Brompton Hospital doctors treat largest number of premature babies with pioneering catheter interventions <span>Royal Brompton Hospital doctors treat largest number of premature babies with pioneering catheter interventions</span> <span><span>H.Virgo</span></span> <span>Wed, 13/11/2019 - 12:45</span> <div class="field field--name-field-date field--type-datetime field--label-hidden field--item"><time datetime="2019-11-13T12:00:00Z">13 November 2019</time></div> <div class="field field--name-body field--type-text-with-summary field--label-hidden field--item"><p>Doctors at Royal Brompton Hospital have treated more babies using cardiac catheter interventions than any other centre in Europe. </p> <p>More than 80 premature babies with Patent Ductus Arteriosus (PDA) – a life threatening congenital heart defect which causes a leak between blood vessels from an opening in the heart – have been treated at the hospital using this pioneering catheter procedure.</p> <p><img alt="Claire Buckle, paediatric cardiology consultant Carles Bautista and Professor Alain Fraisse" data-entity-type="file" data-entity-uuid="f99f4ab8-4795-42e6-adbd-6e5eee2bd139" src="" class="align-right" /></p> <p>Professor Alain Fraisse, consultant paediatric cardiologist at the Trust, carried out the first of this type of catheter intervention in October 2016. </p> <p>The procedure involves inserting a small device made from wire mesh into the heart (through a catheter inserted via a vein in the baby’s leg) and blocks the opening in the heart to stop the leak. It is guided into place using echocardiography imaging, which uses sound waves to capture moving images and is the most widely used technique for non-invasive imaging of the heart.  </p> <p>The procedure takes just 20 minutes and avoids the need for open heart surgery – a complex procedure in tiny babies.</p> <p>Professor Fraisse said: “This procedure offers young paediatric patients and their families hope through a less invasive treatment than surgery, with a shorter hospital stay with no chest scar.”</p> <p>Babies sent to Royal Brompton for treatment were referred by 20 different neonatal intensive care units across the country, as the Trust is the only centre in the UK to have a PDA referral team, which was set up and is led by paediatrics matron Claire Buckle.  </p> <p>Claire said: “The numbers show that we really are leading the way for the treatment of Patent Ductus Arteriosus and we have successfully treated infants weighing as little as 800g.”  </p> <p>The large number of babies treated at the centre has been facilitated with help from Royal Brompton & Harefield Hospitals Charity, who funded the purchase of a new incubator, allowing the team to treat twice as many babies.</p> <p>Gill Raikes, chief executive of the charity, said: “It’s wonderful to be able to support the work Professor Fraisse and his team are doing for premature babies and their families, as without their interventions many of these infants would not survive.”</p> <p>Professor Fraisse added: “We’re extremely grateful to the charity for providing funds for another incubator, allowing us to treat more babies.</p> <p>“Our success has been a real team effort, combining the talents and expertise of cardiologists, anaesthetists and nurses. It’s thanks to this that we have been able to use this pioneering procedure to treat the largest number of premature babies in Europe.” </p></div> Wed, 13 Nov 2019 12:45:54 +0000 H.Virgo 2564 at Trust lung expert warns about potential dangers of vaping <span>Trust lung expert warns about potential dangers of vaping</span> <span><span>H.Virgo</span></span> <span>Tue, 12/11/2019 - 11:16</span> <div class="field field--name-field-date field--type-datetime field--label-hidden field--item"><time datetime="2019-11-12T12:00:00Z">12 November 2019</time></div> <div class="field field--name-body field--type-text-with-summary field--label-hidden field--item"><p><span><span>The fluid in e-cigarettes may cause a potentially life threatening lung inflammation in those who are susceptible, according to research published today. </span></span></p> <p><span><span>The research, co-authored by Royal Brompton’s consultant paediatric chest physician Professor Andrew Bush, outlines a case of hypersensitivity pneumonitis – a condition in which the air sacs and airways in the lungs become severely inflamed – in a 16 year old boy, who was initially suspected of having worsening asthma.</span></span></p> <p><span><span>The teenager developed respiratory failure and needed external assistance for his heart and lungs to work properly, and was placed on extracorporeal membrane oxygen (ECMO) and intravenous antibiotics and steroids.</span></span></p> <p><span><span>The trigger for his condition is thought to have been an immune response to one of the chemicals found in e-cigarette fluid. The report concludes that e-cigarettes should not automatically be considered much safer than tobacco.</span></span></p> <p><span><span>Professor Andrew Bush, said: "This case is very disturbing. We simply do not know the long-term consequences of vaping. We don't know what is in these devices and liquids, therefore, how can we possibly say they are safe to inhale into our lungs? They should be kept out of the hands of young people."</span></span></p> <p><span><span>The research is published in <em><a href="">Archives of Disease in Childhood</a></em>.</span></span></p></div> Tue, 12 Nov 2019 11:16:13 +0000 H.Virgo 2562 at Royal Brompton Clinical Trials team scores hat trick at Clinical Research Awards <span>Royal Brompton Clinical Trials team scores hat trick at Clinical Research Awards</span> <span><span>S.Anand</span></span> <span>Fri, 08/11/2019 - 15:23</span> <div class="field field--name-field-date field--type-datetime field--label-hidden field--item"><time datetime="2019-11-08T12:00:00Z">8 November 2019</time></div> <div class="field field--name-body field--type-text-with-summary field--label-hidden field--item"><p><span><span><span>The Royal Brompton Cystic Fibrosis (CF) Clinical Trials team celebrated three well-deserved wins at the North West London Clinical Research Awards, where they were recognised for their outstanding work carrying out ground-breaking CF research. </span></span></span></p> <p><img alt="" data-entity-type="file" data-entity-uuid="40d22de8-6be2-460a-831d-449193b5f0a3" src="" class="align-right" /><span><span><span>At yesterday’s inaugural North West London Clinical Research Awards, Professor Jane Davies, honorary consultant in paediatric </span></span></span><span><span><span>respiratory medicine at Royal Brompton & Harefield NHS Foundation Trust, and several multidisciplinary members of the trials team accepted the award for outstanding collaborative working. This award recognised the team’s outstanding collaborative work delivering better clinical research to patients and the public. In addition, Professor Davies received the award for outstanding principal investigator, and Rebecca Dobra, Clinical Research Fellow, received the ‘Rising Star’ award. </span></span></span></p> <p><span><span><span>Nominations were judged by a panel of staff and patient representatives from across North West London, as well as a patient representative. </span></span></span></p> <p><span><span><span>The team, which has many years’ experience running trials of new medicines, is supported by the Cystic Fibrosis Trust’s <a href="">Clinical Trials Accelerator Platform</a> (CTAP).</span></span></span></p> <p><span><span><span>The Trials Accelerator has given Royal Brompton Hospital the capacity to scale up on clinical trials in partnership with a network of other London CF Centres, which include King’s College, Great Ormond Street and the Barts Hospitals.</span></span></span></p> <p><span><span><span>The partnership was established by Professor Davies, <span>leader of the network, to share expertise and position trials optimally across each of the centres. The network is a flagship of the Trials Accelerator, with trial activity now taking place across the capital and providing valuable opportunities for referrals between teams. This way the London population of around 2,000 people with CF have fairer opportunities to </span><a href=""><span>take part in ground-breaking trials</span></a><span>.</span></span></span></span></p> <p><span><span><span>Professor Davies, who is also a Professor in Paediatric Respirology & Experimental Medicine at Imperial College London, said yesterday afternoon: “We are delighted to have been recognised in this endeavour by the <a href="">National Institute for Health Research</a>'s Clinical Research Network, North West London. I’d like to take this opportunity to thank the Cystic Fibrosis Trust for their funding, our collaborators for all their hard work, but most of all the people with CF and their families, who have worked so hard with us to bring new drugs through trials to clinical reality. We really couldn’t have done any of it without you!” </span></span></span></p> <p><span><span><span><span>The Clinical Trials Accelerator Platform is a UK-wide initiative, launched in 2017, </span><a href="">to bring together CF centres</a><span>, to increase participation and improve access to CF clinical trials. </span></span></span></span></p> <p> </p></div> Fri, 08 Nov 2019 15:23:53 +0000 S.Anand 2557 at